Nuveen
CAMP icon

Nuveen’s CAMP4 Therapeutics CAMP Stock Holding History

Nuveen’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$182K Buy
45,087
+3,039
+7% +$12.5K ﹤0.01% 3816
2026
Q2 		$184K Buy
+42,048
New +$181K ﹤0.01% 3658

Other funds holding CAMP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Landscape Capital Management
Landscape Capital Management Englewood, New Jersey $1.34B AUM 18.69% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Nuveen's CAMP Position: Q3 2026 in Review

Nuveen increased its CAMP4 Therapeutics (CAMP) stake by 7.2% in Q3 2026, buying an estimated $12.5K and bringing the position to 45,087 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #3816.

Nuveen first reported a position in CAMP in Q2 2026 and has held it in 2 quarters since. The position peaked at $184K in Q2 2026. 27 funds tracked by Wall St. Rank hold CAMP as of Q3 2026.

  • Nuveen held 45,087 shares of CAMP4 Therapeutics worth $182K as of Q3 2026.
  • Nuveen bought 3,039 CAMP4 Therapeutics shares in Q3 2026, an estimated $12.5K.
  • CAMP4 Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #3816 holding.
  • Nuveen first reported a position in CAMP4 Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Nuveen's CAMP4 Therapeutics position peaked at $184K in Q2 2026.
  • 27 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.